Author: admin

Enterprise Monitoring Market 2029: Size, Share, Top Opportunities, Emerging Trends, Leading Companies, and Future Scope

“Microsoft(US), IBM (US), Cisco (US), Dynatrace (US), Datadog (US), New Relic (US), Elastic N.V. (US), (US), BMC Software (US), Zoho Corporation (India), Logic Monitor (US), SolarWinds (US), Paessler (Germany), Trianz (US), ScienceLogic (US), Grafana Labs (US), VirtualMetric (Netherlands), Coralogix (US), Nagios (US), Pandora FMS (Spain), Sumo Logic (US), Atatus (India).”
Enterprise Monitoring Market by Platform (Infrastructure, Application Performance, Security, Digital Experience, Workforce Operation), Digital Experience Platform (Synthetics, Real User Experience, Web Performance) – Global Forecast to 2029.

The enterprise monitoring market is expected to expand at a compound annual growth rate (CAGR) of 18.0% from USD 35.12 billion in 2024 to USD 80.26 billion by 2029. Businesses are increasingly using data-driven decision-making to assist in decision-making processes. Organizations look for monitoring solutions because they need to have real-time insights into operations, customers, and market trends. The need for sophisticated monitoring tools has increased due to the growing emphasis on data-driven decision-making and the requirement to guarantee application performance, security, and compliance.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=178153789

The major factors driving the market growth of enterprise monitoring are the increasing sophistication of IT ecosystems and the need for real-time insights. with the growing adoption of cloud computing, hybrid environments, and distributed architecture. Monitoring solutions are essential for managing visibility, performance, and security across diverse environments.

Another key factor is the rapidly increasing data volumes. Because customer communications and in-house operations generate a large amount of data, it is essential for an organization to employ sophisticated solutions that help analyze this data and make potentially valuable conclusions. This real-time analysis is very important in business and organizations to enable informed decisions, improved processes, and, therefore, competitive advantages.

The workforce operations platforms are projected to register the highest CAGR during the forecast period.

The workforce operations platforms are indispensable tools for enhancing employee efficiency and boosting the effectiveness of professionals within enterprises. These platforms offer detailed insights into the workforce, such as employees’ efficiency, engagement, and procedural activities. With the help of such information, one can notice existing inefficiencies or potential bottlenecks and optimize employees’ work and resource use. Components usually include working hours, schedules, performance reviews, and feedback systems. Workforce operations platforms provide insights into workforce trends, staffing needs, and training plans. Additionally, they offer live updates and real-time visuals, helping managers monitor team performance more effectively. Employing workforce operations platforms can align their human resource strategies with broader business goals, improving performance and fostering stronger organizational commitment.

The Intrusion Detection and Prevention systems (IDPS) segment of the security platform is estimated to contribute the largest market share in the enterprise monitoring market.

Intrusion Detection and Prevention systems (IDPS) are essential for security platforms specified in the enterprise monitoring market. These systems check network traffic and look for malicious activities using signature-based, anomaly-based, or stateful protocol analysis systems. They can be installed in a network solution or as a part of a host solution. IDPS notifies an organization of intrusions and also prevents those intrusions. It blocks the traffic generated by the intruder and notifies the administrator. Key features of IDPS include real-time monitoring, automated responses, quantitative analysis, and account management.

Based on region, Asia Pacific is projected to register the highest CAGR during the forecast period.

The enterprise monitoring market in the Asia Pacific includes China, Japan, ANZ, South Korea, India, and the Rest of Asia Pacific. The Asia Pacific region is one of the rising markets for the enterprise monitoring marketplace owing to the digital transformation, growing use of cloud services, and AI solutions. However, Asian countries such as China, Japan, South Korea, and India, along with Australia and New Zealand, are pioneers in using cloud-native monitoring systems along with big data and analytics using AI. The market is driven by concerns regarding the potential for hacking into sensitive data and the necessity for compliance with regulations established in sectors such as manufacturing, telecommunications, and finance. This is largely due to the increasing demand for real-time data monitoring of equipment and operational processes.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=178153789

Unique Features in the Enterprise Monitoring Market

The Enterprise Monitoring Market is uniquely characterized by its ability to provide real-time visibility and proactive issue detection across diverse IT infrastructures. Unlike traditional monitoring tools, enterprise-grade solutions integrate end-to-end observability, enabling businesses to track system performance, application health, and user experience simultaneously. This helps enterprises prevent downtime and ensure seamless business continuity.

A distinguishing feature of this market is the increasing use of AI-driven predictive analytics and automation. Enterprise monitoring tools leverage machine learning to detect anomalies, forecast potential failures, and automate remediation steps, significantly reducing mean time to resolution (MTTR). This intelligent approach allows organizations to stay ahead of issues instead of reacting after disruptions occur.

Another unique aspect is the holistic monitoring of hybrid and multi-cloud environments. As businesses adopt diverse cloud strategies, enterprise monitoring solutions offer unified dashboards that integrate data from on-premises, private cloud, and public cloud systems. This centralized visibility reduces complexity and helps enterprises optimize workloads, costs, and security in distributed infrastructures.

The market also stands out for its focus on compliance, governance, and security monitoring. Modern enterprise monitoring platforms not only track performance but also ensure adherence to regulatory standards by providing detailed audit logs, access control, and real-time threat detection. This convergence of performance and security monitoring is critical for risk management.

Major Highlights of the Enterprise Monitoring Market

The Enterprise Monitoring Market is witnessing rapid growth due to the rising complexity of IT environments. Organizations are increasingly adopting hybrid and multi-cloud infrastructures, which has created a strong demand for monitoring solutions that deliver unified visibility and control across distributed systems.

A key highlight is the integration of AI, machine learning, and automation into monitoring platforms. These advancements are transforming monitoring from reactive to proactive, enabling anomaly detection, predictive insights, and self-healing mechanisms that reduce downtime and improve overall system resilience.

Another major highlight is the growing emphasis on user experience monitoring (UEM). Enterprises are focusing not only on backend system performance but also on the quality of digital experiences for end-users. Monitoring solutions now provide end-to-end visibility from infrastructure to application layers, ensuring seamless service delivery.

The market is also marked by the convergence of performance, security, and compliance monitoring. With regulatory requirements and cyber risks increasing, enterprise monitoring tools are evolving to offer real-time compliance checks, log management, and integrated threat detection alongside performance tracking.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=178153789

Top Companies in the Enterprise Monitoring Market

The report profiles key players such as Microsoft(US), IBM (US), Cisco (US), Dynatrace (US), Datadog (US), New Relic (US), Elastic N.V. (US), (US), BMC Software (US), Zoho Corporation (India), Logic Monitor (US), SolarWinds (US), Paessler (Germany), Trianz (US), ScienceLogic (US), Grafana Labs (US), VirtualMetric (Netherlands), Coralogix (US), Nagios (US), Pandora FMS (Spain), Sumo Logic (US), Atatus (India), Zabbix (Latvia), Checkmk (Germany), Logz.io (US), Icinga (Germany), Hubstaff (US), and EfficientLab (US).

Cisco (US)

Cisco Systems, Inc. is a US-based multinational digital communications technology company. It operates through several key business segments, each tailored to address distinct technology needs across diverse industries. The company’s Secure, Agile Networks segment encompasses core networking technologies, such as switching, enterprise routing, wireless, and compute products, offering hardware and software solutions. Meanwhile, the Internet for the Future segment focuses on routed optical networking, 5G, silicon, and optics solutions, featuring similar revenue recognition dynamics. Collaboration, another significant segment of the company, includes meetings, collaboration devices, calling, contact centers, and CPaaS offerings, predominantly comprising software with distinct upfront and ratable revenue recognition models. The End-to-End Security segment covers cloud and application security, industrial security, network security, and user and device security offerings, involving hardware and software solutions with distinct recognition patterns.

By applying an acquisition strategy and leveraging new technologies, Cisco has positioned itself as an essential Enterprise monitoring solution provider. With over 200 acquisitions, Cisco has gained critical capabilities in artificial intelligence, cloud computing, and cybersecurity. Among the notable acquisitions were AppDynamics and Splunk, which helped Cisco offer advanced monitoring tools and integrate solutions with zero-trust security frameworks. Through automation, analytics, and machine learning, it has been easier for organizations to manage their networks and increase operational effectiveness. Since adopting such a proactive strategy on the necessity of shifting according to market needs and expectations, the company could position itself as one of the go-to providers for the complete outsourcing of monitoring for enterprises.

Dynatrace (US)

Dynatrace’s principal business offers software intelligence in application, infrastructure, and user experience monitoring and management. The company primarily works towards providing Al-powered observability and automaton features to enable organizations to address cloud intricacies and accelerate digital business outcomes. Since its inception, the company has offered its Dynatrace platform, that contains solutions for the full spectrum of infrastructure monitoring, application and microservice, runtime application protection, digital and business, and cloud automation analytics, among others.

The company has steadily transformed into a leader in the Enterprise monitoring market through mergers and acquisitions, strategic partnerships, and innovation. For instance, in 2024, Runecast was acquired and integrated into security platforms and compliance solutions using artificial intelligence for the client’s security posture management. Dynatrace has developed an integrated platform for actionable insights and observability that can address a wide range of complex issues across the entire IT ecosystem. This platform also provides advanced guidance for automated remediation, enhancing its ability to resolve problems without manual intervention.

Microsoft (US)

Microsoft provides enterprise monitoring solutions through its Azure Monitor platform, enabling businesses to collect, analyze, and act on telemetry data from applications and infrastructure. This helps organizations enhance performance, maintain system reliability, and ensure security across their cloud and on-premises environments.

Paessler (Germany)

Paessler is known for its PRTG Network Monitor, a comprehensive enterprise monitoring solution that helps businesses monitor their IT infrastructure, networks, and devices. It offers real-time visibility, alerts, and customizable dashboards, enabling efficient monitoring and management of complex enterprise environments.

Trianz (US

Trianz provides advanced enterprise monitoring solutions designed to enhance IT performance, security, and compliance. Their services offer real-time insights into critical systems, helping businesses optimize operations, detect anomalies, and improve decision-making across various enterprise environments.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/enterprise-monitoring-market-178153789.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Enterprise Monitoring Market 2029: Size, Share, Top Opportunities, Emerging Trends, Leading Companies, and Future Scope

Power Transformer Market worth $41.62 Billion by 2030

The global power transformer market is projected to grow from estimated $30.38 billion in 2025 to $41.62 billion by 2030, at a CAGR of 6.5% during the 2025-2030.

The global Power Transformer Market is projected to grow from estimated USD 30.38 billion in 2025 to USD 41.62 billion by 2030, at a CAGR of 6.5% during the forecast period. The growth of the Power Transformer Market is largely driven by the increasing need to reinforce power distribution and transmission infrastructure in response to the rising global demand for electricity. Additionally, the market benefits from the expanding integration of renewable energy sources and significant investments in industrial development, fueling the demand for efficient and high-capacity power transformers. A notable growth catalyst is the accelerating adoption of high-voltage direct current (HVDC) systems, which require advanced transformer solutions for long-distance, high-efficiency power transmission, further propelling the market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128022787

Air-cooled is expected to be the fastest-growing segment in the Power Transformer Market from 2025 to 2030

The air-cooled segment is expected to register the highest CAGR in the Power Transformer Market during the forecast period due to its growing adoption in urban and indoor applications where space constraints, fire safety, and environmental considerations are critical. Air-cooled transformers eliminate the need for oil, reducing fire hazards and minimizing environmental risks, making them ideal for commercial buildings, hospitals, data centers, and other sensitive infrastructures. Their low maintenance, ease of installation, and enhanced safety features align with the increasing focus on sustainable and reliable power solutions. Additionally, insulation and thermal management technology advancements have improved their performance, supporting wider deployment across developed and developing regions.

Medium (61–600 MVA) power rating segment is expected to hold the largest market share

The medium (61–600 MVA) segment is expected to hold the largest market share in 2024 due to its broad applicability across various end-use sectors, including utilities, industrial facilities, and infrastructure projects. These transformers are crucial for sub-transmission and regional distribution networks, where they effectively bridge the gap between high-voltage transmission systems and lower-voltage distribution grids. As urbanization accelerates and electricity demand surges, particularly in emerging economies, there is a growing need to expand and modernize power infrastructure—driving demand for medium power transformers. Their ability to handle substantial loads while offering flexibility in installation and configuration makes them ideal for integration into expanding grid systems, renewable energy projects, and industrial operations. Additionally, ongoing investments in smart grid development and rural electrification further support the dominance of this segment in the global Power Transformer Market.

Asia Pacific is projected to be the fastest-growing region in the Power Transformer Market between 2025 and 2030

Asia Pacific is projected to be the fastest-growing market for power transformers, driven by a combination of economic, infrastructural, and policy-related factors. Rapid industrialization and urbanization in key countries, such as China and India, as well as Southeast Asian countries, have led to a sharp rise in electricity demand, prompting large-scale investments in expanding and modernizing power grid infrastructure. Governments are also actively promoting the adoption of renewable energy to meet international climate goals and reduce reliance on fossil fuels. This transition requires integrating large-scale solar and wind energy projects into national grids, boosting the demand for advanced power transformers to handle high voltages and ensure efficient long-distance power transmission. Additionally, initiatives aimed at enhancing rural electrification and replacing outdated infrastructure with more energy-efficient solutions further drive the market. These combined efforts reinforce the region’s leadership in the global Power Transformer Market, positioning the region as a key driver of future industry expansion.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=128022787

Key Market Players

Key players in the global Power Transformer Market include Hitachi Energy (Japan), General Electric (US), Siemens (Germany), Mitsubishi Electric (Japan), Eaton Corporation (Ireland), Hyundai Electric (South Korea), Schneider Electric (France), Fuji Electric (Japan), Toshiba Energy System & Solution Corporation (Japan), and CG Power and Industrial Solutions (India).

Hitachi Energy (Switzerland)

Hitachi Energy is a prominent force in the global energy sector, recognized for its innovative technologies and strong commitment to sustainable energy solutions. With a robust international presence, the company is vital in advancing energy infrastructure worldwide. In the power transformer domain, it stands out as a leading manufacturer, offering a comprehensive portfolio of high-performance transformers designed to meet industrial, commercial, and utility requirements. Its offerings span distribution transformers for localized applications to large-scale power transformers for high-voltage transmission networks. These solutions are engineered for superior reliability, efficiency, and environmental sustainability. By harnessing advanced technologies and maintaining a strong focus on continuous improvement, it ensures its transformer systems adhere to the highest standards of quality and operational performance. Despite challenges such as intense market competition and evolving regulatory frameworks, it remains agile and forward-thinking, consistently innovating to meet the dynamic demands of the power transformer market. With a steadfast focus on customer-centric solutions and environmental stewardship, it continues to lead the way in shaping a more sustainable and resilient global energy future.

Eaton (Ireland)

Eaton is a globally recognized power management company operating in over 175 countries, with a workforce of approximately 85,000 employees. Known for its robust engineering expertise and diversified product offerings, the company delivers innovative and sustainable solutions across sectors such as electrical, aerospace, hydraulics, and vehicle industries. In the power transformer market, it is a prominent player, offering a comprehensive range of distribution and power transformers designed for utility, industrial, and commercial applications. These transformers are gaining popularity due to their efficiency, durability, and eco-friendly performance, integrating advanced features, such as smart monitoring, fault detection, and grid compatibility. It emphasizes resilient infrastructure and energy-efficient technologies, aligning its transformer solutions with global trends in grid modernization, electrification, and renewable energy integration. While it faces industry-wide challenges, such as supply chain constraints and volatile raw material prices, it remains well-positioned through its focus on digitalization, sustainability, and customer-centric innovation. Its strategic investments in green technologies and smart grid capabilities further strengthen its competitive edge, making it a key contributor to the evolving power transformer landscape worldwide.

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: newsletter@marketsandmarkets.com

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/power-transformers-market-128022787.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Power Transformer Market worth $41.62 Billion by 2030

Top Los Altos, CA Realtor Leverages Extensive Industry Network to Deliver Results in Competitive Bay Area Market

Los Altos, CA – Professional networks and established relationships within the real estate industry create significant advantages for clients navigating the competitive Bay Area market. Experienced agents who have cultivated strong connections over decades of practice can leverage these relationships to benefit their clients through insider knowledge, strategic positioning, and collaborative opportunities that newer agents simply cannot access.

Shelly Potvin’s reputation as a real estate agent in Los Altos, CA is built on 26 years of successful transactions throughout the Peninsula and Silicon Valley regions. Her extensive experience has created a comprehensive network where listing agents at nearly every open house personally know or have previously worked with her. This professional recognition translates into tangible benefits for her clients, including access to properties before they hit the market and enhanced negotiation positioning during competitive bidding situations.

First-time homebuyers particularly benefit from Potvin’s patient approach and educational guidance throughout the complex purchasing process. As a dedicated Realtor agent in Los Altos, CA, she demonstrates remarkable patience with clients who require extended timelines to make decisions, working through evolving budgets, changing preferences, and shifting mortgage regulations. Her commitment extends well beyond closing day, with regular check-ins and ongoing support that reflects her philosophy of making client goals her own personal mission.

Potvin’s credentials include a Masters in Management and certification as an Accredited Staging Professional (ASP), providing comprehensive expertise for both buyers and sellers. Among Realtors in Los Altos, CA, her sharp instincts for neighborhood selection and strategic contingency placement have consistently saved clients significant money while positioning them competitively in multiple-offer situations.

“I LOVE every minute of working with buyers and sellers alike,” said Shelly Potvin, Realtor. “For me, the job isn’t over, really ever. I default to going above and beyond, and doing so with class.”

Whether you’re a first-time buyer or experienced investor, Potvin’s extensive network and proven expertise deliver exceptional results. As a trusted real estate listing agent in Los Altos, CA, she provides the guidance and support needed for successful transactions. Contact Shelly Potvin at http://www.shellypotvin.com/ to experience the advantages of working with a truly connected industry professional.

Media Contact
Company Name: Shelly Potvin | Real Estate Agent in Los Altos CA
Contact Person: Shelly Potvin
Email: Send Email
Phone: +1 650-303-7501
Address:467 1st St
City: Los Altos
State: California 94022
Country: United States
Website: http://www.shellypotvin.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Los Altos, CA Realtor Leverages Extensive Industry Network to Deliver Results in Competitive Bay Area Market

Castleman Disease Pipeline Insight 2025: Targeted Immunotherapies, Novel Cytokine Blockers, and Precision Medicine Approaches Lead Development | DelveInsight

“Castleman Disease Pipeline Insight”
The therapeutic pipeline for Castleman disease, a rare and heterogeneous group of lymphoproliferative disorders, continues to expand, with innovative therapies addressing both unicentric (UCD) and multicentric (MCD) subtypes. Current treatment options rely on surgery for UCD and immunosuppressive or anti–IL-6–based regimens for MCD. However, treatment resistance, relapse rates, and limited efficacy in HHV-8–negative/idiopathic multicentric Castleman disease (iMCD) highlight ongoing unmet needs.

DelveInsight’s “Castleman Disease – Pipeline Insight, 2025” reviews a growing portfolio of novel approaches that move beyond conventional immunosuppression. Monoclonal antibodies targeting IL-6 and its receptor, along with second-generation cytokine blockers, are being optimized to improve response rates and long-term disease control. Emerging therapies include JAK/STAT pathway inhibitors, next-generation B-cell–directed therapies, and immune checkpoint modulators, designed to address the inflammatory and immune dysregulation underpinning MCD. Precision-based strategies such as biomarker-guided treatment selection and genomic profiling are shaping clinical trial designs, ensuring more tailored therapeutic interventions.

The 2025 pipeline reflects a paradigm shift in Castleman disease management—from symptom suppression toward disease modification. Backed by regulatory incentives for rare diseases and rising collaboration between academia, biotech innovators, and global foundations, the field is poised to deliver more durable, patient-centric therapies. With biologics, small molecules, and immune modulators progressing through clinical stages, the Castleman disease landscape is evolving toward broader treatment access and long-term remission potential.

Interested in learning more about the current treatment landscape and the key drivers shaping the Castleman Disease pipeline? Click here

 

Key Takeaways from the Castleman Disease Pipeline Report

• DelveInsight’s Castleman Disease pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for Castleman Disease treatment.

• The leading Castleman Disease companies include Senhwa Biosciences, and others are evaluating their lead assets to improve the Castleman Disease treatment landscape.

• Key Castleman Disease pipeline therapies in various stages of development include Fulvestrant, Bicalutamide, and others.

• The only FDA-approved therapy for idiopathic multicentric Castleman disease (iMCD) remains Sylvant (siltuximab). It was initially approved on April 23, 2014, for HIV-negative, HHV-8-negative MCD

• A clinical trial evaluating ruxolitinib (a JAK inhibitor) in adults with previously treated iMCD is currently underway. The study was listed with a start date of July 25, 2025.

• A remarkable case report published February 5, 2025, described a patient with relapsing iMCD who achieved 24-month remission after treatment with adalimumab, a TNF-blocking agent. This finding, which highlights a novel therapeutic approach, was noted in a letter to the editor in the New England Journal of Medicine

• No new FDA approvals or regulatory actions specific to Castleman disease have occurred recently through mid-2025.

 

Castleman Disease Overview

Castleman Disease (CD) is a rare disorder characterized by abnormal growth of lymph node tissue, leading to lymphoproliferation. It primarily presents in two forms: Unicentric Castleman Disease (UCD), which affects a single lymph node region and is usually localized and asymptomatic or causes symptoms due to compression of nearby structures; and Multicentric Castleman Disease (MCD), which involves multiple lymph node regions and is associated with systemic symptoms like fever, fatigue, weight loss, and enlarged organs. MCD can be caused by human herpesvirus-8 (HHV-8), especially in immunocompromised patients, or occur as idiopathic MCD without a known viral cause.

The underlying mechanism in MCD often involves excessive production of inflammatory cytokines, particularly interleukin-6 (IL-6), driving widespread inflammation and lymph node proliferation. Treatment depends on the disease subtype and severity, ranging from surgical removal for UCD to targeted therapies such as anti-IL-6 antibodies (e.g., siltuximab), immunosuppressants, antivirals, or chemotherapy for MCD. Early diagnosis and appropriate management are essential to control symptoms and improve outcomes.

Find out more about Castleman Disease medication at https://www.delveinsight.com/report-store/castleman-disease-pipeline-insight

 

Castleman Disease Treatment Analysis: Drug Profile

Silmitasertib: Senhwa Biosciences

Silmitasertib (CX-4945), developed by Senhwa Biosciences, has been shown in clinical studies to effectively target CK2 and modulate the intended pathways without causing toxicity. As a single-agent CK2 inhibitor, CX-4945 has demonstrated clinical benefits, including stable disease and prolonged treatment duration in several patients. Additionally, combining CX-4945 with DNA-damaging chemotherapy agents like gemcitabine (Gemzar) and cisplatin (Platinol) has exhibited synergistic effects, enhancing the overall efficacy of these anticancer therapies.

Learn more about the novel and emerging Castleman Disease pipeline therapies.

 

Castleman Disease Therapeutics Assessment

By Product Type

• Mono

• Combination

• Mono/Combination.

 

By Stage

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 

By Route of Administration

• Oral

• Parenteral

• intravitreal

• Subretinal

• Topical

 

By Molecule Type

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

 

Scope of the Castleman Disease Pipeline Report

• Coverage: Global

• Key Castleman Disease Companies: Senhwa Biosciences, and others.

• Key Castleman Disease Pipeline Therapies: Fulvestrant, Bicalutamide, and others.

Explore detailed insights on drugs used in the treatment of Castleman Disease here.

 

Table of Contents

1. Introduction

2. Executive Summary

3. Castleman Disease Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Castleman Disease Pipeline Therapeutics

6. Castleman Disease Pipeline: Late-Stage Products (Phase III)

7. Castleman Disease Pipeline: Mid-Stage Products (Phase II)

8. Castleman Disease Pipeline: Early Stage Products (Phase I)

9. Therapeutic Assessment

10. Inactive Products

11. Company-University Collaborations (Licensing/Partnering) Analysis

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Castleman Disease Pipeline Insight 2025: Targeted Immunotherapies, Novel Cytokine Blockers, and Precision Medicine Approaches Lead Development | DelveInsight

Cardiogenic Shock Pipeline Insight 2025: Novel Biologics, Mechanical Support Devices, and Advanced Pharmacotherapies Drive Clinical Innovation | DelveInsight

“Cardiogenic Shock Pipeline Insight”
The cardiogenic shock pipeline is advancing rapidly, with novel approaches targeting its high mortality and limited treatment options. Current care relies on vasopressors, inotropes, and mechanical circulatory support (IABP, ECMO), which offer temporary stabilization but lack targeted pharmacologic therapies and long-term solutions—highlighting a major unmet need.

DelveInsight’s “Cardiogenic Shock – Pipeline Insight, 2025” highlights a diverse and expanding portfolio of candidates in clinical and preclinical stages. Emerging biologics—including regenerative cell-based therapies and gene therapies—are being investigated to restore myocardial function and reduce irreversible damage. Novel pharmacotherapies such as selective inotropes, metabolic modulators, and vasodilator–inotrope hybrids are under development to enhance cardiac output with fewer adverse effects compared to standard agents. Meanwhile, next-generation mechanical support platforms, including percutaneous ventricular assist devices and miniaturized ECMO systems, are advancing with the goal of improving hemodynamic stabilization and patient outcomes.

The 2025 cardiogenic shock pipeline demonstrates a strategic transition toward integrated treatment models, combining pharmacological innovation with device-based solutions. With growing research investment, supportive regulatory pathways, and increasing recognition of cardiogenic shock as a critical unmet area in cardiology, the pipeline holds promise to transform management—shifting from crisis stabilization to comprehensive, outcome-driven therapies.

Interested in learning more about the current treatment landscape and the key drivers shaping the cardiogenic shock pipeline? Click here

 

Key Takeaways from the Cardiogenic Shock Pipeline Report

• DelveInsight’s cardiogenic shock pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for cardiogenic shock treatment.

• The leading cardiogenic shock companies include Windtree Therapeutics, Leading BioSciences, and others are evaluating their lead assets to improve the cardiogenic shock treatment landscape.

• Key cardiogenic shock pipeline therapies in various stages of development include Silmitasertib and others.

• In July 2025, the U.S. FDA approved a labeling supplement for IMOVAX Rabies to add a 2-dose pre-exposure prophylaxis (PrEP) regimen (in addition to the 3-dose schedule), referencing NCT03700242 and NCT04127786.

• In July 2025, a Publication in the European Journal of Heart Failure highlighted compassionate-use data showing reversal of shock within 48 hours in three terminally ill patients treated with procizumab. The Phase 2a clinical trial is set to initiate in mid-2025 across 11 centers in Europe.

• In December 2024, the FDA granted premarket approval (PMA) to expand the indication of certain Impella pumps (Impella CP with SmartAssist and Impella 5.5 with SmartAssist) for treating acute decompensated heart failure and cardiogenic shock in pediatric patients, with weight thresholds of ≥52 kg and ≥30 kg, respectively.

 

Cardiogenic Shock Overview

Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body’s needs, leading to inadequate tissue perfusion and oxygen delivery. It most commonly occurs as a severe complication of acute myocardial infarction (heart attack), but can also result from other causes such as severe heart failure, cardiomyopathy, or valvular heart disease. Patients typically present with low blood pressure, rapid heartbeat, cold and clammy skin, confusion, and signs of poor organ perfusion like reduced urine output.

The management of cardiogenic shock involves rapid diagnosis and aggressive treatment to restore adequate circulation. This includes supportive care with fluids, medications to improve heart contractility (inotropes), and sometimes mechanical circulatory support devices like intra-aortic balloon pumps or ventricular assist devices. Treating the underlying cause, such as reopening blocked coronary arteries in a heart attack, is critical. Despite advances in care, cardiogenic shock remains associated with high mortality, emphasizing the need for prompt intervention.

Find out more about cardiogenic shock medication at https://www.delveinsight.com/report-store/cardiogenic-shock-pipeline-insight

 

Cardiogenic Shock Treatment Analysis: Drug Profile

Istaroxime: Windtree Therapeutics

Istaroxime, developed by Windtree Therapeutics, is a first-in-class luso-inotropic agent currently in Phase 2 clinical development. It acts as a powerful positive inotrope by enhancing myocardial contractility through inhibition of the Na⁺/K⁺-ATPase enzyme. Additionally, istaroxime promotes myocardial relaxation by activating the SERCA2a calcium pump, offering a dual mechanism of action.

Learn more about the novel and emerging cardiogenic shock pipeline therapies.

 

Cardiogenic Shock Therapeutics Assessment

By Product Type

• Mono

• Combination

• Mono/Combination.

 

By Stage

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 

By Route of Administration

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

 

By Molecule Type

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

 

Scope of the Cardiogenic Shock Pipeline Report

• Coverage: Global

• Key Cardiogenic Shock Companies: Windtree Therapeutics, Leading BioSciences, and others.

• Key Cardiogenic Shock Pipeline Therapies: Silmitasertib, and others.

Explore detailed insights on drugs used in the treatment of cardiogenic shock here.

 

Table of Contents

1. Introduction

2. Executive Summary

3. Cardiogenic Shock Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Cardiogenic Shock Pipeline Therapeutics

6. Cardiogenic Shock Pipeline: Late-Stage Products (Phase III)

7. Cardiogenic Shock Pipeline: Mid-Stage Products (Phase II)

8. Cardiogenic Shock Pipeline: Early Stage Products (Phase I)

9. Therapeutic Assessment

10. Inactive Products

11. Company-University Collaborations (Licensing/Partnering) Analysis

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cardiogenic Shock Pipeline Insight 2025: Novel Biologics, Mechanical Support Devices, and Advanced Pharmacotherapies Drive Clinical Innovation | DelveInsight

Top Real Estate Listing Agent in Petaluma, CA Generates 12 Offers and Over-Asking Price Sales in Competitive Market Conditions

Petaluma, CA – Exceptional marketing strategies and professional staging capabilities continue to drive outstanding results in today’s competitive real estate market. Properties that receive comprehensive preparation and strategic positioning consistently attract multiple qualified buyers, resulting in bidding situations that benefit sellers through above-market pricing and favorable terms.

Jen Birmingham’s expertise as a Realtor agent in Petaluma, CA includes professional-quality staging that transforms properties into showcase homes. Her aesthetic eye and attention to detail create environments that resonate with potential buyers, often generating comments from other real estate professionals who inquire about the staging services used. This comprehensive approach to property presentation has resulted in some listings receiving over 150 visitors during showing periods.

Birmingham’s commitment to ethical representation sets her apart in the industry, as she maintains strict boundaries regarding dual agency situations. As a dedicated real estate agent in Petaluma, CA, she refuses to represent buyers on her own listings, ensuring that each client receives undivided advocacy throughout the transaction process. This principle-based approach contrasts with agents who build business models around representing both sides of transactions, potentially compromising client interests.

The Compass Concierge program has become a cornerstone of Birmingham’s seller services, with over twenty successful implementations helping clients access equity for pre-sale improvements. Realtors in Petaluma, CA who utilize this innovative financing option enable sellers to complete necessary renovations and enhancements without upfront costs, often resulting in significantly higher sale prices that exceed the preparation investments.

“I will only ever represent one side in a sale, to ensure that client is well taken care of,” said Jen Birmingham, real estate agent. “From the moment we start working together, my clients’ goals become mine.”

Client experiences consistently demonstrate Birmingham’s ability to exceed expectations, with families reporting smooth processes and exceptional outcomes even during challenging market conditions. For sellers seeking maximum results and ethical representation, Birmingham provides the expertise and integrity needed for success. As a trusted Realtor in Petaluma, CA, she delivers comprehensive services that prioritize client interests above all else.

Contact Jen Birmingham at https://www.jenbirmingham.com/ to experience her proven approach to achieving outstanding real estate results.

Media Contact
Company Name: Jen Birmingham | Real Estate Agent in Petaluma, CA
Contact Person: Jen Birmingham
Email: Send Email
Phone: +1 707-364-2618
Address:127 Fourth St.
City: Petaluma
State: California 94952
Country: United States
Website: https://www.jenbirmingham.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Listing Agent in Petaluma, CA Generates 12 Offers and Over-Asking Price Sales in Competitive Market Conditions

Celiac Disease Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Celiac Disease Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Celiac Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Celiac Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Celiac Disease Treatment Landscape @ Celiac Disease Pipeline Outlook

Key Takeaways from the Celiac Disease Pipeline Report

  • On 15 August 2025, Sanofi announced a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE).
  • On 08 August 2025, Topas Therapeutics GmbH conducted a Phase 2a study to evaluate the safety, tolerability, and PD effects of two infusions of TPM502 in adult patients diagnosed with CeD. The patient´s participation in the study comprises 3 phases: screening period, treatment period and follow-up period.
  • DelveInsight’s Celiac Disease pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Celiac Disease treatment.
  • The leading Celiac Disease Companies such as Sanofi, Entero Therapeutics, Takeda, Pfizer, Topas Therapeutics, Anokion SA, Protagonist Therapeutics, Equillium, AMYRA Biotech AG, Forte Biosciences, LAPIX Therapeutics, Ahead Therapeutics, Lumen Bioscience, IGY Life Sciences and others.
  • Promising Celiac Disease Pipeline Therapies such as KAN-101, Amlitelimab, TPM502, Ritlecitinib, ALV003, TEV-53408 and others.

Discover groundbreaking developments in Celiac Disease Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Celiac Disease Ongoing Clinical Trials Assessment

Celiac Disease Emerging Drugs Profile

  • TAK-062: Takeda

TAK-062 is a potential best-in-class, highly potent super glutenase – a protein that degrades ingested gluten that was computationally engineered to treat celiac disease. In this serious autoimmune disease, the ingestion of gluten leads to inflammation and damage in the small intestine. TAK-062 has high specificity for immunogenic fractions of gluten peptides and can degrade >99% of even high amounts of gluten in a complex study meal in the human stomach and in vitro. The Phase I study investigated TAK-062’s safety and tolerability in healthy volunteers and people with celiac disease. The ability of TAK-062 to degrade ingested gluten was studied in healthy volunteers. It is designed to lessen the immune-reactive parts of gluten before they exit the stomach to prevent the immune response to gluten and eliminate the symptoms and intestinal damage caused by celiac disease. Takeda has initiated a Phase IIb study efficacy and dose-ranging study of TAK-062 in patients with the uncontrolled disease who maintain a gluten-free diet.

  • KAN-101: AnokionSA

KAN-101 is an investigational therapy developed by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA, aimed at treating celiac disease, a chronic autoimmune condition triggered by gluten. This drug is designed to induce immune tolerance to gliadin, a component of gluten, by leveraging a liver-targeting platform that engages specific receptors in the liver to promote a natural immune tolerance pathway. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Celiac disease.

  • MTX 101: Mozart Therapeutics

MTX-101 is a bispecific autoimmune checkpoint inhibitor. It’s dual configuration binds the CD8 Treg receptors, KIR and CD8, to selectively activate CD8 Treg and enhance MTX-101’s specificity, respectively. MTX-101 is designed to restore CD8 Treg functionality and the cytolytic elimination of pathogenic CD4 T cells. This autoimmune checkpoint inhibitor aims to restore the intrinsic functions of regulatory CD8 T cells, acting early in the autoimmune disease process to suppress and eliminate pathogenic autoimmune cells, halt downstream inflammation, and prevent tissue destruction. MTX-101 is being developed for early stage and slowly-progressing autoimmune diseases, such as type 1 diabetes mellitus and celiac disease. Currently the drugs is in Phase I stage of development for the treatment of celiac disease.

The Celiac Disease Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
  • Celiac Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market

Stay informed about the Celiac Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Celiac Disease Unmet Needs

Celiac Disease Companies

Sanofi, Entero Therapeutics, Takeda, Pfizer, Topas Therapeutics, Anokion SA, Protagonist Therapeutics, Equillium, AMYRA Biotech AG, Forte Biosciences, LAPIX Therapeutics, Ahead Therapeutics, Lumen Bioscience, IGY Life Sciences and others.

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Celiac Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Transform your understanding of the Celiac Disease Pipeline! See the latest progress in drug development and clinical research @ Celiac Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Celiac Disease Pipeline Report

  • Coverage- Global
  • Celiac Disease Companies- Sanofi, Entero Therapeutics, Takeda, Pfizer, Topas Therapeutics, Anokion SA, Protagonist Therapeutics, Equillium, AMYRA Biotech AG, Forte Biosciences, LAPIX Therapeutics, Ahead Therapeutics, Lumen Bioscience, IGY Life Sciences and others.
  • Celiac Disease Pipeline Therapies- KAN-101, Amlitelimab, TPM502, Ritlecitinib, ALV003, TEV-53408 and others.
  • Celiac Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Celiac Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Immunological and Autoimmune Disorders Research–Access the Full Celiac Disease Pipeline Analysis Today! @ Celiac Disease Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Celiac Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Celiac Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Mid Stage Products (Phase II)
  10. TAK-062: Takeda
  11. Early Stage Products (Phase I)
  12. MTX 101: Mozart Therapeutics
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Celiac Disease Key Companies
  17. Celiac Disease Key Products
  18. Celiac Disease- Unmet Needs
  19. Celiac Disease- Market Drivers and Barriers
  20. Celiac Disease- Future Perspectives and Conclusion
  21. Celiac Disease Analyst Views
  22. Celiac Disease Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/celiac-disease-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Celiac Disease Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Anaplastic Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Anaplastic Thyroid Cancer Pipeline Insight 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It covers the Anaplastic Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anaplastic Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Anaplastic Thyroid Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Anaplastic Thyroid Cancer Pipeline Outlook

Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report

  • In August 2025, University of Arizona announced a Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.
  • DelveInsight’s Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
  • The leading Anaplastic Thyroid Cancer Companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
  • Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.

Stay ahead with the most recent pipeline outlook for Anaplastic Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with Anaplastic Thyroid Cancer @ Anaplastic Thyroid Cancer Treatment Drugs

Anaplastic Thyroid Cancer Emerging Drugs Profile

  • Sapanisertib: Takeda

Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. Sapanisertib has demonstrated promising single-agent activity in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (NSCLC) and exhibits differential anti-tumor activity compared to rapalog inhibitors of TORC1 in NRF2-mutant squamous NSCLC in vivo models.

  • HLX208: Shanghai Henlius Biotech

BRAF V600E small-molecule inhibitor can be potentially used in the treatment of various solid tumors. HLX208 may be combined with the Company’s proprietary EGFR or PD-1 targeted antibodies to enhance a high-quality, innovative and differentiated product portfolio for the treatment of various cancer types.

The Anaplastic Thyroid Cancer Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
  • Anaplastic Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market

Explore groundbreaking therapies and clinical trials in the Anaplastic Thyroid Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Anaplastic Thyroid Cancer Drugs

Anaplastic Thyroid Cancer Companies

Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.

Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Anaplastic Thyroid Cancer Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, Anaplastic Thyroid Cancer Pipeline developments, and key companies with DelveInsight’s expert analysis @ Anaplastic Thyroid Cancer Market Drivers and Barriers

Scope of the Anaplastic Thyroid Cancer Pipeline Report

  • Coverage- Global
  • Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
  • Anaplastic Thyroid Cancer Pipeline Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar, BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.
  • Anaplastic Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Anaplastic Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Anaplastic Thyroid Cancer Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Anaplastic Thyroid Cancer Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Anaplastic Thyroid Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anaplastic Thyroid Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Sapanisertib: Takeda
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AIC100: AffyImmune Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Anaplastic Thyroid Cancer Key Companies
  21. Anaplastic Thyroid Cancer Key Products
  22. Anaplastic Thyroid Cancer- Unmet Needs
  23. Anaplastic Thyroid Cancer- Market Drivers and Barriers
  24. Anaplastic Thyroid Cancer- Future Perspectives and Conclusion
  25. Anaplastic Thyroid Cancer Analyst Views
  26. Anaplastic Thyroid Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anaplastic Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Gene Therapy Competitive Landscape Report 2025 | DelveInsight

DelveInsight’s, “Gene Therapy Competitive landscape, 2025,” report provides comprehensive insights about 180+ companies and 200+ drugs in Gene Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Gene Therapy Treatment Landscape @ Gene Therapy Pipeline Outlook

Key Takeaways from the Gene Therapy Competitive Landscape Report

  • On 17 August 2025, MeiraGTx LLC conducted a study of individual participation in this study will be approximately 54 months for participants who received AAV-GAD in Study MGT-GAD-025 and approximately 60 months for participants who received sham surgery in Study MGT-GAD-025.
  • On 15 August 2025, Janssen Research & Development LLC organized a Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene.
  • On 13 August 2025, REGENXBIO Inc. announced a phase I/II/III study to evaluate the safety, tolerability, pharmacodynamics (microdystrophin protein levels), pharmacokinetic, and clinical efficacy of RGX-202 when administered IV as one-time dose to ambulant male participants with Duchenne. A comprehensive, short-term, prophylactic immunosuppression regimen will be administered during treatment to mitigate a potential immune response. This study is being conducted in three sequential parts: a phase I/II study (Part 1), a phase 3 pivotal study (Part 2) and a confirmatory study (Part 3). Part 1 will study a one-time dose of RGX-202 (1×10^14 or 2×10^14 GC/kg) in up to 15 participants with Duchenne.
  • DelveInsight’s Gene Therapy Competitive landscape report depicts a robust space with 180-+ active players working to develop 200+ pipeline therapies for Gene Therapy treatment.
  • The leading Gene Therapy Companies such as Pfizer, Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, Adverum Biotechnologies, Kyverna Therapeutics, Vivet Therapeutics, HELIXMITH Co, Rocket Pharmaceuticals, Bristol-Myers Squibb, Wellington Zhaotai Therapies, Reyon Pharmaceutical, Neowise Biotechnology, Orna Therapeutics, Genflow Biosciences, Xylocor Therapeutics, Kolon TissueGene, Allogene Therapeutics, Nanjing IASO Biotherapeutics, Shanghai Vitalgen BioPharma, Rui Therapeutics, Obsidian Therapeutics, YolTech Therapeutics, Neurotech USA, Beacon Therapeutics, REGENXBIO and others.
  • Promising Gene Therapy Therapies such as Tipifarnib, Sucrose (3%), Chemotherapy, UX111, SPK-8011, SBT101, Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib and others.

Discover groundbreaking developments in Gene Therapy Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Gene Therapy Clinical Trials Assessment

Gene Therapy Marketed Therapies

  • Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, company use innovative science and digital technologies to create transformative treatments in areas of great medical need. In quest to find new medicines, consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and are finding innovative ways to expand access to company latest treatments. Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, company is working to turn promising gene therapies into proven treatments.

  • Zolgensma

Zolgensma (onasemnogene abeparvovec) is the only gene therapy for spinal muscular atrophy (SMA) and the only SMA treatment designed to directly address the genetic root cause of the disease by replacing the function of the missing or non-working SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time IV infusion. Zolgensma was approved by the US Food and Drug Administration for the treatment of pediatric patients less than 2years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. . Zolgensma is now approved in more than 40 countries and more than 2,000 patients have been treated with Zolgensma globally across clinical trials, managed access programs, and in the commercial setting.

  • Spark Therapeutics

Spark Therapeutics, is a fully integrated company committed to discovering, developing and delivering gene therapies, challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. The company have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, there is the path to a world where no life is limited by genetic disease.

  • LUXTURNA

LUXTURNA is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease (IRD) and the first adeno-associated virus (AAV) vector gene therapy approved in the U.S. LUXTURNA was approved by FDA under Priority Review and previously received orphan drug and breakthrough therapy designations from FDA. With the approval of LUXTURNA, FDA will issue to Spark Therapeutics a Rare Pediatric Disease Priority Review Voucher for a Priority Review of a subsequent marketing application for a different product. Spark Therapeutics’ Marketing Authorization Application (MAA) for LUXTURNA is currently under review with the European Medicines Agency (EMA). LUXTURNA also has received orphan product designations from EMA.

Gene Therapy Pipeline Therapies

  • Pfizer

Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849 when it was founded by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company is engaged in the discovery, development, manufacture, and sale of medicines and vaccines across various therapeutic areas such as vaccines, oncology, internal medicine, hospital, inflammation and immunology, and rare diseases. Pfizer’s dedication to global health is evident through its extensive portfolio of medicines and vaccines that aim to enhance wellness, prevention, treatments, and cures for various diseases. The company collaborates with healthcare providers, governments, and communities worldwide to expand access to reliable and affordable healthcare services.

  • Fordadistrogene movaparvovec

Fordadistrogene movaparvovec is an investigational recombinant adeno-associated virus serotype 9 (AAV9) capsid carrying a shortened version of the human dystrophin gene (mini-dystrophin) under the control of a human muscle-specific promotor. The AAV9 capsid was chosen as the delivery mechanism because of its potential to target muscle tissue. The FDA has lifted a clinical hold on Pfizer’s phase III clinical trial of its investigational gene therapy, fordadistrogene movaparvovec, in patients with Duchenne muscular dystrophy (DMD). Regulatory and ethics approvals to resume the CIFFREO Phase III ambulatory study, including the FDA’s lift of its clinical hold, follow reviews of data and protocol amendments. Currently the drug is in Phase III stage of development for the treatment of Duchenne muscular dystrophy

  • Ultragenyx Pharmaceutical Inc

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, the company apply cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – The company focus on purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity.

  • DTX401

DTX401 is an investigational AAV8 gene therapy designed to deliver stable expression and activity of G6Pase-α using a single intravenous infusion. Long term Phase I/II data demonstrate an acceptable safety profile and durability of response. All treated patients have experienced stable or improved glucose control while tapering or discontinuing oral glucose replacement therapy with cornstarch after receiving DTX401. The Phase III GlucoGene study is underway to evaluate the ability of DTX401 to reduce the use of cornstarch while maintaining or improving glucose control as well as the therapy’s impact on patients’ quality of life. DTX401 was granted Orphan Drug Designation in the United States, EU and United Kingdom, and Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation in the United States. DTX401 was accepted into the EMA’s Priority Medicines program (PRIME), enabling more frequent interactions with the EMA and the potential for an accelerated approval.The drug has recently completed Phase III clinical trial for the treatment of patients with Glycogen storage disease type I.

  • Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket’s first AAV-based gene therapy program targets Danon disease, a rare neuromuscular and cardiovascular disease.

  • RP-L102

RP-L102 is a gene therapy product containing autologous (patient-derived) hematopoietic stem cells (HSCs) that have been genetically modified with a lentiviral vector to contain a functional copy of the FANCA gene. If given early in life, RP-L102 gene therapy has the potential to serve as a preventative measure, correcting bone marrow cells before there is progression to severe bone marrow failure. RP-L102 has been granted Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations for the treatment of Fanconi Anemia type A in the United States and Orphan Drug designation in Europe. The drug is currently in Phase II stage of development for the treatment of patients with Fanconi Anemia (FA).

  • Adverum Biotechnologies

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with neovascular or wet age-related macular degeneration.

  • ADVM-022

ADVM022 is being developed for the treatment of wet AMD. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach) ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD. The OPTIC trial is designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. The drug is currently in Phase II stage of development for the treatment of patients with Wet AMD.

  • Kyverna Therapeutics

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including two ongoing multi-center, open-label Phase I trials of KYV-101 in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. By advancing more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated.

  • KYV-101

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase I trial in oncology. Results were published by the NIH in Nature Medicine. Kyverna is currently conducting trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additional clinical trials of KYV-101 in systemic sclerosis, and myasthenia gravis are in preparation. The drug is currently in Phase I/II stage of development for the treatment of patients with Lupus nephritis.

  • Vivet Therapeutics

Vivet Therapeutics is a private, clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic conditions, including Wilson’s disease. Vivet’s gene therapy platform uses recombinant adeno-associated viruses (rAAVs) as vectors and has initiated two clinical programs and four pre-clinical assets to date. Its most advanced therapy is VTX-801, a novel gene therapy for Wilson’s disease, with key clinical read-outs expected by the end of 2024. Vivet Therapeutics was founded in 2016 by CEO Dr Jean-Philippe Combal and CSO Dr Gloria Gonzalez-Aseguinolaza and is led by a highly experienced management team with deep expertise developing gene therapies and orphan drugs.

  • VTX-802

VTX-802 is an AAV-based gene therapy for patients with Progressive Familial Intrahepatic Cholestasis Type 2. It delivers a codon-optimized version of the BSEP gene to the liver and is currently under preclinical testing. The drug is currently in Preclinical stage of development for the treatment of patients with Intrahepatic cholestasis.

Gene Therapy Analytical Perspective by DelveInsight

  • In-depth Commercial Assessment: Gene Therapy Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

  • Gene Therapy Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Gene Therapy Report Assessment

  • Company Analysis
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Transform your understanding of the Gene Therapy Pipeline! See the latest progress in drug development and clinical research @ Gene Therapy Market Drivers and Barriers, and Future Perspectives

Scope of the Gene Therapy Competitive Landscape Report

  • Coverage- Global
  • Gene Therapy Companies- Pfizer, Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, Adverum Biotechnologies, Kyverna Therapeutics, Vivet Therapeutics, HELIXMITH Co, Rocket Pharmaceuticals, Bristol-Myers Squibb, Wellington Zhaotai Therapies, Reyon Pharmaceutical, Neowise Biotechnology, Orna Therapeutics, Genflow Biosciences, Xylocor Therapeutics, Kolon TissueGene, Allogene Therapeutics, Nanjing IASO Biotherapeutics, Shanghai Vitalgen BioPharma, Rui Therapeutics, Obsidian Therapeutics, YolTech Therapeutics, Neurotech USA, Beacon Therapeutics, REGENXBIO and others.
  • Gene Therapy Analytical Perspective: In-depth Commercial Assessment
  • Gene Therapy Unmet Needs, Preclinical and Discovery Stage Products

Stay Ahead in Oncology Research–Access the Full Gene Therapy Pipeline Analysis Today! @ Gene Therapy Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Gene Therapy: Overview
  4. Gene Therapy -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. Gene Therapy: Company and Product Profiles (Marketed Therapies)
  8. Novartis
  9. Zolgensma
  10. Gene Therapy: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Pfizer
  13. Fordadistrogene movaparvovec
  14. Mid Stage Products (Phase II)
  15. Rocket Pharmaceuticals
  16. RP-L102
  17. Early Stage Products (Phase I/II)
  18. Kyverna Therapeutics
  19. KYV-101
  20. Preclinical and Discovery Stage Products
  21. Vivet Therapeutics
  22. VTX-802
  23. Inactive Products
  24. Gene Therapy- Unmet needs
  25. Gene Therapy – Market drivers and barriers
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gene-therapy-competitive-landscape

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene Therapy Competitive Landscape Report 2025 | DelveInsight

Chronic Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Chronic Myeloid Leukaemia Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Myeloid Leukaemia pipeline landscape. It covers the Chronic Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Myeloid Leukemia Treatment Landscape @ Chronic Myeloid Leukemia Pipeline Outlook

Key Takeaways from the Chronic Myeloid Leukemia Pipeline Report

  • On 15 August 2025, M.D. Anderson Cancer Center conducted a phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase.
  • On 13 August 2025, Novartis Pharmaceuticals announced a study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
  • DelveInsight’s Chronic Myeloid Leukemia pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Chronic Myeloid Leukemia treatment.
  • The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others.
  • Promising Chronic Myeloid Leukemia Pipeline Therapies such as Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2’deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others.

Discover groundbreaking developments in Chronic Myeloid Leukemia Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Chronic Myeloid Leukemia Ongoing Clinical Trials Assessment

Chronic Myeloid Leukemia Emerging Drugs Profile

  • Navtemadlin : Kartos Therapeutics

Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor. Currently, the drug is undergoing an Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML).

  • Ropeginterferon alfa 2b : AOP Orphan Pharmaceuticals

Ropeginterferon alfa-2b was discovered by PharmaEssentia Corp. based in Taiwan. BESREMi (Ropeginterferon alfa-2b) is a novel, long-acting, mono-pegylated proline interferon .Its pharmacokinetic properties offer a new level of tolerability.

The Chronic Myeloid Leukemia Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Myeloid Leukemia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Myeloid Leukemia Treatment.
  • Chronic Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Myeloid Leukemia market

Stay informed about the Chronic Myeloid Leukemia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Chronic Myeloid Leukemia Unmet Needs

Chronic Myeloid Leukemia Companies

Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others.

Chronic Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type

Chronic Myeloid Leukemia Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type

Transform your understanding of the Chronic Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ Chronic Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Myeloid Leukemia Pipeline Report

  • Coverage- Global
  • Chronic Myeloid Leukemia Companies- Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others.
  • Chronic Myeloid Leukemia Pipeline Therapies- Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2’deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others.
  • Chronic Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Chronic Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Chronic Myeloid Leukemia Pipeline Analysis Today! @ Chronic Myeloid Leukemia Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Chronic Myeloid Leukaemia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Myeloid Leukaemia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name : Company Name
  9. Mid Stage Products (Phase I/ II)
  10. Navtemadlin: Kartos Therapeutics
  11. Early Stage Products (Phase I)
  12. Drug Name: Company Name
  13. Preclinical and Discovery Stage Products
  14. Drug Name: Company Name
  15. Inactive Products
  16. Chronic Myeloid Leukaemia Key Companies
  17. Chronic Myeloid Leukaemia Key Products
  18. Chronic Myeloid Leukaemia- Unmet Needs
  19. Chronic Myeloid Leukaemia- Market Drivers and Barriers
  20. Chronic Myeloid Leukaemia- Future Perspectives and Conclusion
  21. Chronic Myeloid Leukaemia Analyst Views
  22. Chronic Myeloid Leukaemia Key Companies

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies